Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
== Early career, Minister of Finance, and first presidential run (1999–2018) == Peña joined the Industrial Development Fund as an analyst in 1999 and served as an economist at the Central Bank of Paraguay from 2000 to 2009. He was appointed as one of the four directors of the Central Bank of Paraguay in 2012, leaving his job at the IMF.
Classification of nerve damage was well-defined by Sir Herbert Seddon and Sunderland in a system that remains in use. The adjacent table details the forms (neurapraxia, axonotmesis and neurotmesis) and degrees of nerve injury that occur as a result of exposure to various temperatures, with the intent to interrupt nerve traffic and relieve pain. Cryoneurolysis treatments that use nitrous oxide (boiling point of −88.5 °C) as the coolant fall in the range of an axonotmesis injury, or 2nd degree injury, according to the Sunderland classification system. Treatments of the nerve in this temperature range are reversible, usually within a few months. Nerves treated in this temperature range experience a disruption of the axon, with Wallerian degeneration occurring distal to the site of injury. The axon and myelin sheath are affected, but all of the connective tissues (endoneurium, perineurium, and epineurium) remain intact. Following Wallerian degeneration, the axon regenerates along the original nerve path at a rate of approximately 1–2 mm per day. Cryoneurolysis differs from cryoablation in that cryoablation treatments use liquid nitrogen (boiling point of −195.8 °C) as the coolant, and therefore, fall into the range of a neurotmesis injury, or 3rd degree injury according to the Sunderland classification. Treatments of the nerve in this temperature range are irreversible. Nerves treated in this temperature range experience a disruption of both the axon and the endoneurium connective tissue layer.
=== Kinematic viscosity === In fluid dynamics, it is sometimes more appropriate to work in terms of kinematic viscosity (sometimes also called the momentum diffusivity), defined as the ratio of the dynamic viscosity (μ) over the density of the fluid (ρ). It is usually denoted by the Greek letter nu (ν):
Van Buren (1829), member of New York State Assembly Henry Ledyard (1830), mayor of Detroit; president of Newport Hospital Henry Nicoll (1830), U.S. congressman from New York Henry C. Murphy (1830), U.S. congressman from New York; former U.S. ambassador to the Netherlands John L. O'Sullivan (1831), US minister to Portugal; journalist who coined the term " Manifest Destiny"; publisher of The United States Magazine and Democratic Review James William Beekman (1834), member of the New York State Senate; vice-president of the New York Hospital Isaac C. Delaplaine (1834), U.S. congressman from New York John Richardson Thurman (1835), U.S. congressman from New York John Jay (1836), grandson of Chief Justice John Jay; United States minister to Austro-Hungary; president of the American Historical Association John Vanderbilt (1837), judge, member of the New York State Senate William Ward Duffield (1841), officer, member of the Michigan Senate, superintendent of the U.S. National Geodetic Survey Abram Stevens Hewitt (1842), former mayor of New York City and planner of the first line of the New York City Subway system; Chairman of the Democratic National Committee 1876–1877, son-in-law of philanthropist Peter Cooper Edward Cooper (1842), former mayor of New York City and son of industrialist Peter Cooper Nicholas B. La Bau (1844), member of the New York State Assembly and the New York State Senate John Winthrop Chanler (1847), U.S. congressman from New York Horace Carpentier (1848), first mayor of Oakland, California and president of the Overland Telegraph Company A.
Sources: en.wikipedia.org
=== Phase 3 === Gepirone (Ariza; BMY-13805; Exxua; Gepirone ER; MJ-13805; Org-33062; TGFK-07AD; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor partial agonist [1] Lysergic acid diethylamide (LSD; lysergide; MM-120; MM120) – non-selective serotonin receptor agonist and psychedelic hallucinogen [2] [3] Toludesvenlafaxine extended release (4-methylbenzoate desvenlafaxine; ansofaxine; desvenlafaxine prodrug; LPM-570065; LY-03005; Ruoxinlin) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) [4] Vilazodone (EMD-68843; SB-659746A; Viibryd) – serotonin reuptake inhibitor (SRI) and serotonin 5-HT1A receptor partial agonist [5]
=== Legal status === Cipaglucosidase alfa is available in the UK, since June 2021, under the Early Access to Medicines Scheme. In December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Pombiliti, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Amicus Therapeutics Europe Limited. Cipaglucosidase alfa was approved for medical use in the European Union in March 2023.
In 1972, Sweden introduced a law that made it possible to change a person's legal gender, but in order to do that, transgender individuals were required to be sterilized and were not allowed to save any sperm or eggs. Apart from this, there were no other mandatory surgeries required for legal gender change. In 1999, people who had been forcibly sterilized in Sweden were entitled to compensation. However, the sterilization requirement remained for people who changed their legal gender. In January 2013, forced sterilization was banned in Sweden. Depending on the person's health and wishes there are several different treatments and surgeries available. Today, no form of treatment is mandatory. Although to access medical and legal transitional treatment (e.g. hormone replacement therapy, and top surgery to enhance or remove breast tissue), the person will need to be diagnosed with transexualism or gender dysphoria, which requires at least one year of therapy, during which they must live for one full year as their desired gender in all professional, social, and personal matters. Gender clinics are recommended to provide male-to-female patients with wigs and breast prostheses for the endeavor. The evaluation additionally involves, if possible, meetings with family members and/or other individuals close to the patient. Patients may be denied care for any number of "psychosocial dimensions", including their choice of job or their marital status.
She was active in that role for over ten years. During that time she was also elected into the Association of American Physicians. In 2015 Dr. Huttenlocher was inducted as a Member of the National Academy of Medicine "for her pioneering studies of cell migration and alterations of cell migration in human diseases." In 2017, Huttenlocher was awarded a UW2020 grant to support her project "Engineering leukocytes generated from human iPS cells to treat human disease." At the same time, she was also elected a Fellow of the American Society for Cell Biology. In May 2020, Huttenlocher was named the Anna Ruth Brummett Professor of Pediatrics and Medical Microbiology and Immunology Chair in honor of her "major contributions to the advancement of knowledge." The following year, she was part of a large team of researchers from the University of Wisconsin Carbone Cancer Center recognized with the Society for the Immunotherapy of Cancer’s Team Science Award for "long-standing contribution to the field of cancer immunotherapy over the past 35 years." Huttenlocher's recent research projects include "Cell migration and wound repair" and "Imaging immunometabolism in live animals during host defense." In 2023, Huttenlocher published the book "From Loss to Memory: Behind the Discovery of Synaptic Pruning". It describes the discovery of synaptic pruning and its current relevance to early learning, autism, schizophrenia and Alzheimer's disease.
==== Diabetes ==== The high doses of nicotinic acid used to treat hyperlipidemia have been shown to elevate fasting blood glucose in people with type 2 diabetes. Long-term nicotinic acid therapy was also associated with an increase in the risk of new-onset type 2 diabetes.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.